{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:59:58Z","timestamp":1789171198863,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Direcci\u00f3n General de Farmacia y Productos Sanitarios (Ministerio Espa\u00f1ol de Sanidad, Pol\u00edtica Social e Igualdad)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1245\/s10434-021-11087-7","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T10:03:12Z","timestamp":1637661792000},"page":"2617-2625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial"],"prefix":"10.1245","volume":"29","author":[{"given":"Cascales Campos Pedro","family":"Antonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonz\u00e1lez Gil","family":"Alida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil G\u00f3mez","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonz\u00e1lez S\u00e1nchez","family":"Roc\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ednez Garc\u00eda","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso Romero Jos\u00e9","family":"Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieto D\u00edaz","family":"An\u00edbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barcel\u00f3 Valc\u00e1rcel","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f3mez Ruiz \u00c1lvaro","family":"Jes\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00edrez Romero","family":"Pablo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil Mart\u00ednez","family":"Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"11087_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin."},{"key":"11087_CR2","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950\u20135.","journal-title":"N Engl J Med."},{"key":"11087_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001\u20137.","journal-title":"J Clin Oncol."},{"key":"11087_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med."},{"key":"11087_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ygyno.2009.01.007","volume":"112","author":"JL Walker","year":"2009","unstructured":"Walker JL. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol. 2009;112:439\u201340.","journal-title":"Gynecol Oncol."},{"key":"11087_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1245\/s10434-006-9167-9","volume":"14","author":"D Elias","year":"2006","unstructured":"Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2006;14:509\u201314.","journal-title":"Ann Surg Oncol."},{"key":"11087_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ejso.2010.01.006","volume":"36","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36:456\u201362.","journal-title":"Eur J Surg Oncol."},{"key":"11087_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3109\/02656736.2015.1075071","volume":"31","author":"K Stamou","year":"2015","unstructured":"Stamou K, Tsamis D, Pallas N, et al. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a case series and review of the literature. Int J Hyperthermia. 2015;31:850\u20136.","journal-title":"Int J Hyperthermia."},{"key":"11087_CR9","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737\u201343.","journal-title":"J Clin Oncol."},{"key":"11087_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sonke GS, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.","journal-title":"N Engl J Med."},{"key":"11087_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJMe1714556","volume":"378","author":"DR Spriggs","year":"2018","unstructured":"Spriggs DR, Zivanovic O. Ovarian cancer treatment: are we getting warmer? N Engl J Med. 2018;378:293\u20134.","journal-title":"N Engl J Med."},{"key":"11087_CR12","unstructured":"National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Published 9 August 2006 (v3.03: 31 March 2003). Retrieved xxxx at https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"11087_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10585-020-10034-2","volume":"37","author":"A Gonz\u00e1lez-Gil","year":"2020","unstructured":"Gonz\u00e1lez-Gil A, G\u00f3mez-Ruiz \u00c1J, Gil-Mart\u00ednez J, et al. Tako-tsubo syndrome after intraperitoneal hyperthermic chemotherapy (HIPEC) with cisplatin: an unusual complication of cytoreductive surgery plus HIPEC. Clin Exp Metastasis. 2020;37:445\u20136.","journal-title":"Clin Exp Metastasis."},{"key":"11087_CR14","first-page":"30444","volume":"S0748-7983","author":"SN Koole","year":"2019","unstructured":"Koole SN, Kieffer JM, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, et\u00a0al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Eur J Surg Oncol. 2019;S0748-7983:30444\u20135.","journal-title":"Eur J Surg Oncol."},{"key":"11087_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejso.2018.10.528","volume":"45","author":"Y Wang","year":"2019","unstructured":"Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: a systematic review and meta-analysis. Eur J Surg Oncol. 2019;45:301\u20139.","journal-title":"Eur J Surg Oncol."},{"key":"11087_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1080\/02656736.2019.1612101","volume":"36","author":"Q Wu","year":"2019","unstructured":"Wu Q, Wu Q, Xu J, et al. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis. Int J Hyperthermia. 2019;36:562\u201372.","journal-title":"Int J Hyperthermia."},{"key":"11087_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","volume":"41","author":"YR Huo","year":"2015","unstructured":"Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41:1578\u201389.","journal-title":"Eur J Surg Oncol."},{"key":"11087_CR18","doi-asserted-by":"publisher","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","volume":"3","author":"Z Lei","year":"2020","unstructured":"Lei Z, Wang Y, Wang J, et al. Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer. JAMA Netw Open. 2020;3:e2013940.","journal-title":"JAMA Netw Open."},{"key":"11087_CR19","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.19.00091","volume":"37","author":"I Vergote","year":"2019","unstructured":"Vergote I, Harter P, Chiva L. Is there a role for intraperitoneal chemotherapy, including HIPEC, in the management of ovarian cancer? J Clin Oncol. 2019;37:2420\u20133.","journal-title":"J Clin Oncol."},{"key":"11087_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline ovarian tumours and recurrent disease. Ann Oncol. 2019;30:672\u2013705.","journal-title":"Ann Oncol."},{"key":"11087_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-009-0001-y","volume":"11","author":"M Markman","year":"2009","unstructured":"Markman M. Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression. Curr Oncol Rep. 2009;11:1\u20132.","journal-title":"Curr Oncol Rep."},{"key":"11087_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200124010-00003","volume":"24","author":"PE Kintzel","year":"2001","unstructured":"Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24:19\u201338.","journal-title":"Drug Saf."},{"key":"11087_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2016.05.032","volume":"142","author":"S Gouy","year":"2016","unstructured":"Gouy S, Ferron G, Glehen O, et al. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142:237\u201342.","journal-title":"Gynecol Oncol."},{"key":"11087_CR24","first-page":"1417","volume":"60","author":"SN Gardner","year":"2000","unstructured":"Gardner SN. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and non-specific drugs. Cancer Res. 2000;60:1417\u201325.","journal-title":"Cancer Res."},{"key":"11087_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1006\/gyno.1993.1274","volume":"51","author":"MP Hopkins","year":"1993","unstructured":"Hopkins MP, Shellhaas C, Clark T, Stakleff KS, Jenison EL. The effect of immediate intraperitoneal carboplatinum on wound healing. Gynecol Oncol. 1993;51:210\u20133.","journal-title":"Gynecol Oncol."},{"key":"11087_CR26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ejso.2018.01.005","volume":"44","author":"M Fournier","year":"2018","unstructured":"Fournier M, Huchon C, Ngo C, et al. Morbidity of rectosigmoid resection in cytoreductive surgery for ovarian cancer: risk factor analysis. Eur J Surg Oncol. 2018;44:750\u20133.","journal-title":"Eur J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-11087-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-11087-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-11087-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T09:08:52Z","timestamp":1647594532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-11087-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["11087"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-11087-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}